İçeriğe geç
akaturk Akademik ölçüm

Akademisyen profili · PROFESÖR

DİDEM ŞENER DEDE

ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Tıbbi Onkoloji (İç Hastalıkları)
  • TIP FAKÜLTESİ
  • DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
Makale YÖKSİS 97
Proje 1
Kitap 2
Bildiri 45
Patent 1
Sanatsal 1
Scopus (SJR)
Q1 25 Q2 33 Q3 18 Q4 5
WoS (JCR)
Q1 11 Q2 18 Q3 24 Q4 28
TR Index 8 makale

Scopus (SJR)

WoS (JCR)

TR Index

8 makale

Toplam 97 yayın

Makaleler

  1. 2025 The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer Expert Review of Anticancer Therapy DOI 10.1080/14737140.2025.2490289
  2. 2025 Large Unstained Cells: A Predictive Biomarker for Recurrence and Survival in Resected Gastric Cancer medicina DOI 10.3390/medicina61020208
  3. 2025 Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer Turkish Journal of Medical Sciences DOI 10.55730/1300-0144.6002
  4. 2025 Association of RAD51 expression with response to neoadjuvant treatment and prognosis in locally advanced gastric cancer EXPERT REVIEW OF ANTICANCER THERAPY DOI 10.1080/14737140.2025.2555468
  5. 2025 Synergistic prognostic effect of the renin-angiotensin-aldosterone system and immune-checkpoint inhibition in advanced lung cancer: The SPERICIL study INTERNATIONAL JOURNAL OF CANCER DOI 10.1002/ijc.70169
  6. 2025 Palliative Radiotherapy in Metastatic Breast Cancer Patients on CDK4/6 Inhibitors: Safety Analysis cancers DOI 10.3390/cancers17030424
  7. 2025 Correlation of PD-L1 and HIF-1 Alpha Expression with KRAS Mutation and Clinicopathological Parameters in Non-Small Cell Lung Cancer CURRENT ISSUES IN MOLECULAR BIOLOGY DOI 10.3390/cimb47020121
  8. 2025 The Effect of Positron Emission Tomography-Computed Tomography Parameters on Pathological Response in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Treatment Oncol Res Treat (2025) 48 (7-8): 407–413. DOI 10.1159/000545820
  9. 2024 A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review. J Oncol Pharm Pract DOI 10.1177/10781552241260864
  10. 2024 Large Unstained Cells (LUC): A Novel Predictor of CDK4/6 Inhibitor Outcomes in HR+ HER2-Negative Metastatic Breast Cancer Journal of Clinical Medicine DOI 10.3390/jcm14010173
  11. 2024 Akciğer Kanserinde Epidemiyoloji, Tanı ve Evreleme Turkiye Klinikleri Medical Oncology - Special Topics
  12. 2023 Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations J Cancer Res Ther DOI 10.4103/jcrt.jcrt_353_22
  13. 2023 Do metastatic volumes measured in breast cancer patients with bone metastases correlate with the numbers of skeletal and extraskeletal events? JOINT DISEASES AND RELATED SURGERY DOI 10.52312/jdrs.2023.1333
  14. 2023 Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data PANCREAS DOI 10.1097/MPA.0000000000002238.
  15. 2023 Should clinical trials about prostate cancer assess the frailty as an endpoint? International Urology Nephrology DOI 10.1007/s11255-023-03636-8.
  16. 2022 Efficacy and safety of folfiri plus aflibercept in second‑line treatment of metastatic colorectal cancer: Real‑life data from Turkish oncology group journal of cancer research and therapeutics DOI 10.4103/jcrt.jcrt_1104_21
  17. 2022 Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group) Turk J Med Sci DOI 10.55730/1300-0144.5404.
  18. 2021 Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study J Cancer Res Clin Oncol DOI 10.1007/s00432-020-03501-6
  19. 2021 The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement Journal of Cancer Research and Clinical Oncology DOI 10.1007/s00432-021-03546-1
  20. 2021 Brescia-COVID Respiratory Severity Scale (BRCSS) and Quick SOFA (qSOFA) score are most useful in showing severity in COVID-19 patients Scientific Reports DOI 10.1038/s41598-021-01181-x

Akademisyenlere dön